Mark Vincent
Director/Board Member presso APTOSE BIOSCIENCES INC.
Patrimonio netto: 719 $ in data 31/03/2024
Profilo
Mark D.
Vincent is the founder of Sarissa, Inc. (founded in 2000) where he holds the title of Chief Executive Officer & Director since 2011.
He is currently working as an Independent Director at Aptose Biosciences, Inc. since 2007 and as an Associate Professor at the University of Western Ontario since 2008.
Dr. Vincent has previously worked as a Director at DRI Capital, Inc. and as a Director-Investigational Oncology at YM BioSciences, Inc. He obtained his doctorate degree from the University of Cape Town in 1976.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
APTOSE BIOSCIENCES INC.
0.00% | 05/02/2024 | 433 ( 0.00% ) | 719 $ | 31/03/2024 |
Posizioni attive di Mark Vincent
| Società | Posizione | Inizio |
|---|---|---|
| APTOSE BIOSCIENCES INC. | Director/Board Member | 19/09/2007 |
| Sarissa, Inc. | Founder | 01/01/2000 |
| University of Western Ontario | Corporate Officer/Principal | 01/01/2008 |
Precedenti posizioni note di Mark Vincent
| Società | Posizione | Fine |
|---|---|---|
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Director/Board Member | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formazione di Mark Vincent
| University of Cape Town | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| Aziende private | 3 |
|---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Sarissa, Inc. |
- Borsa valori
- Insiders
- Mark Vincent
